Respiratory Syncytial Virus Infection
33
3
6
23
Key Insights
Highlights
Success Rate
96% trial completion (above average)
Published Results
14 trials with published results (42%)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
3.0%
1 terminated out of 33 trials
95.8%
+9.3% vs benchmark
12%
4 trials in Phase 3/4
61%
14 of 23 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 23 completed trials
Clinical Trials (33)
The Immunology and Safety of Maternal RSV Vaccination (ABRYSVO), Infant Nirsevimab (BEYFORTUS) Immunization, or Both Products
Study of a Respiratory Syncytial Virus/Human Metapneumovirus/Parainfluenza Virus Type 3 Vaccine Candidate in Adults Aged 60 Years and Older
A Phase III Study of Deuremidevir Hydrobromide for the Treatment of RSV Infection in Infants and Young Children
Risk Factors and Severity of Bronchiolitis in Hospitalized Children at Assiut University Hospital
Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine Candidate
Study of a Respiratory Syncytial Virus Candidate Formulation in Adults Aged 60 Years and Older
Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals
Gut Microbiome and Immune Response in Severe RSV Infection in Vietnamese Infants
Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004)
SPECIAL INVESTIGATION FOR ABRYSVO IN INDIVIDUALS AGED 60 YEARS OR OLDER
Study on a Live-attenuated Respiratory Syncytial Virus Vaccine for Assessment of Safety, Transmissibility, and Genetic Stability of the Vaccine Virus Among Close Contacts in Infants and Toddlers 6 to < 24 Months of Age in Puerto Rico (USA)
RSV-Positive Children <5 Years Presenting to Pediatric Emergency Departments in Türkiye: TRUST-RSV
Genotype and Disease Burden of RSV in Older Vietnamese Adults (RSV: Respiratory Syncytial Virus )
A Study to Learn About the Study Medicine Sisunatovir in Adults With Respiratory Syncytial Virus (RSV) Infection
Study of the Safety and Immune Response of an Investigational mRNA Vaccine for the Prevention of Respiratory Syncytial Virus and/or Human Metapneumovirus in Participants Aged 18 to 49 Years and 60 Years and Older
Study of an Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers
Safety and Immunogenicity of the Recombinant Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 18 Years and Older
A Study of Deuremidevir Hydrobromide for Suspension in Chinese Infants Hospitalized With RSV
A Study to Learn How the Study Medicine Called Sisunatovir is Tolerated and Acts in the Bodies of Chinese Healthy Adults.
Molecular and Microbiome/Metagenome Correlates of Recurrent Wheeze in RSV Infected Infants